Related references
Note: Only part of the references are listed.Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
Davey Daniel et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma
Cristina Valero et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer
Xixi Li et al.
FUTURE ONCOLOGY (2020)
Immunotherapeutic approaches for small-cell lung cancer
Wade T. Iams et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
Li Chen et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer
Mila P. Petrova et al.
BIOSCIENCE TRENDS (2020)
The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
Taichi Matsubara et al.
JOURNAL OF THORACIC DISEASE (2020)
Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
Na Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
Wenxian Wang et al.
FRONTIERS IN ONCOLOGY (2020)
The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
Mihaela Aldea et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
Hsiao-Ling Chen et al.
CANCERS (2020)
The prognostic value of pretreatment prognostic nutritional index in patients with small cell lung cancer and it's influencing factors: a meta-analysis of observational studies
Ai-Min Jiang et al.
JOURNAL OF THORACIC DISEASE (2020)
Association of Pre- and Posttreatment Neutrophil-Lymphocyte Ratio With Recurrence and Mortality in Locally Advanced Non-Small Cell Lung Cancer
Nikhil T. Sebastian et al.
FRONTIERS IN ONCOLOGY (2020)
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
Antonio Galvano et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC)
Cem Mirili et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer
Dickran Kazandjian et al.
JAMA ONCOLOGY (2019)
Current Diagnosis and Management of Small-Cell Lung Cancer
Shuhang Wang et al.
MAYO CLINIC PROCEEDINGS (2019)
Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab
Taro Ohba et al.
JOURNAL OF THORACIC DISEASE (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy
Mehmet A. Bilen et al.
CANCER (2019)
Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Huilin Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
Hiren Mandaliya et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Significance of combined preoperative serum Alb and dNLR for diagnosis of pancreatic cancer
Jia-Xin Liu et al.
FUTURE ONCOLOGY (2018)
Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience
Hui Luo et al.
JOURNAL OF CANCER (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma
Gyeong-Won Lee et al.
ACTA HAEMATOLOGICA (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy
Shi Jin et al.
CLINICAL RESPIRATORY JOURNAL (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis
Ruonan Yang et al.
JOURNAL OF CANCER (2018)
The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review
Ross D. Dolan et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer A meta-analysis
Junwu Duan et al.
MEDICINE (2018)
Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients
Hong Hu et al.
WORLD JOURNAL OF UROLOGY (2017)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients
Jarrett J. Failing et al.
MELANOMA RESEARCH (2017)
Prognostic value of systemic immune-inflammation index in patients with gastric cancer
Kang Wang et al.
CHINESE JOURNAL OF CANCER (2017)
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Leora Horn et al.
ONCOLOGIST (2016)
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Small Cell Lung Cancer: Where Do We Go From Here?
Lauren Averett Byers et al.
CANCER (2015)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up
S Sundstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
